E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Atopic Dermatitis |
Atopische Dermatitis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003639 |
E.1.2 | Term | Atopic dermatitis |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of tralokinumab in adults with atopic dermatitis using change from baseline in Eczema Area and Severity Index (EASI)
|
Beurteilung der Wirksamkeit von Tralokinumab bei Erwachsenen mit Atopischer Dermatitis anhand der Veränderung der Ekzemfläche und des EASI zum Ausgangswert bei der Baseline-Visite. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the efficacy of tralokinumab using efficacy measures of Scoring of Atopic Dermatitis (SCORAD) and Investigator's Global Assessment (IGA) in adults with atopic dermatitis - To evaluate the safety and tolerability of tralokinumab in adults with atopic dermatitis - To evaluate the effect of tralokinumab on quality of life in adults with atopic dermatitis - To characterize the pharmacokinetics (PK) and immunogenicity of tralokinumab in adults with atopic dermatitis |
- Bewertung der klinischen Wirksamkeit von Tralokinumab gemessen mit Hilfe der Wirksamkeitsmessgrößen für Atopische Dermatitis (AD) SCORAD und Investigator's Global Assessment (IGA) bei Erwachsenen mit AD - Bewertung der Sicherheit und Verträglichkemittelschwerer bis schwerer AD; - Bewertung des Effekts von Tralokinumab auf die Lebensqualität von Erwachsenen mit AD - Charakterisierung der Pharmakokinetik (PK) und Immunogenität von Tralokinumab bei Erwachsenen mit AD
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18-75 years - Physician diagnosis of atopic dermatitis for > 1 year - Atopic dermatitis involvement of ≥ 15% body surface area - EASI score of ≥ 12 - SCORAD of ≥ 25 - IGA score of ≥ 3 - Effective birth control in line with protocol details |
- im Alter von 18-75 Jahren - klinische Diagnose der Atopischer Dermatitis > 1 Jahr - ASI Wert von ≥ 12 - SCORAD von ≥ 25 - IGA Wert von ≥ 3 - effektive Schwangerschaftsverhütungsmethoden entsprechend den Festlegungen laut Protokoll |
|
E.4 | Principal exclusion criteria |
- History of anaphylaxis following any biologic therapy - Hepatitis B, C or HIV - Pregnant or breastfeeding - History of cancer - Previous receipt of tralokinumab |
- Bekannte anaphylaktische Reaktionen nach Behandlungen mit Biologika - Hepatitis B, C oder HIV-positiv - Schwangere oder stillende Frauen, Frauen in der Stillzeit - Krebserkrankungen in der medizinischen Vorgeschichte - Frühere Anwendung von Tralokinumab
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in EASI at Week 12 |
Veränderung des EASI zwischen Baseline (Ausgangswert) und Woche 12. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Bi-weekly throughout study. |
2-wöchendlich während der Studie
|
|
E.5.2 | Secondary end point(s) |
- Change from baseline in EASI - Safety and tolerability - Percentage of subjects achieving IGA of 0 (clear) or 1 (almost clear) - Change from baseline in SCORAD - Percentage of subjects achieving 50% reduction from baseline in EASI - Percentage of subjects achieving 50% reduction from baseline in SCORAD - Change from baseline in pruritus - Change from baseline in quality of life - Pharmacokinetics of tralokinumab - Immunogenicity of tralokinumab |
- Veränderung des EASI zum Ausgangswert; - Sicherheit und Verträglichkeit von Tralokinumab - Prozentsatz der Patienten, die einen IGA von 0 (geheitl) oder 1 (fast geheilt) erreichen; - Veränderung des SCORAD vom Ausgangswert; - Prozentsatz der Patienten, die eine 50%-ige Reduktion des Ausgangswertes des EASI-Scores erreichen (EASI 50); - Prozentsatz der Patienten, die eine 50%-ige Reduktion des Ausgangswertes des SCORAD erreichen (SCORAD 50); - Veränderung vom Ausgangswert des Juckreizes - Veränderung der Lebensqualität (DLQI) vom Ausgangswert; - Pharmakokinetisches Profil von Tralokinumab; - Immugenität von Tralokinumab |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will be measured up to Week 12 for on-therapy effects and time points beyond end of treatment for off-therapy effects. |
Die sekundären Endpunkte werden bis zur Woche 12 auf on-Therapie-Effekte und an Zeitpunkten über das Ende der Behandlung hinaus für off-Therapie-Effekte gemessen. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Germany |
Japan |
Poland |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit of the last subject undergoing the trial |
letzte Visite des letzten Patienten |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |